Clinical trials: Seizures, Epileptic
Generalized Epilepsy
Monotherapy With Levetiracetam in Newly Diagnosed Patients Suffering From Epilepsy
A double-blind trial comparing the efficacy and safety of levetiracetam to carbamazepine used as monotherapy in subjects (≥ 16 years) newly or recently diagnosed as suffering from epilepsy, and experiencing partial or generalized…
- Trial name
- NCT00150735
- Testing
- LEVETIRACETAM
- Volunteers
- 580 people
- Sponsor
- UCB Pharma
Developmental and Epileptic Encephalopathies, Epileptic Spasms
Ketogenic Diet for Prevention of Epileptic Spasms in Infantile Onset Genetic Epilepsies
Epileptic spasms (ES) are a predominantly infantile seizure type observed frequently in certain genetic disorders. Ketogenic diet (high ratio of fat to carbohydrate/protein) is an established non-medication treatment for…
- Conditions
- Developmental and Epileptic Encephalopathies, Epileptic Spasms, Genetic Epilepsy, Neonatal and Infant Epilepsy
- Trial name
- NCT06700811
- Testing
- Ketogenic diet
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Heather Olson
Menopause, Epilepsy
Hormone Replacement in Menopausal Women With Epilepsy
The goal of this study is to evaluate the effect of synthetic hormone replacement therapy on anti-seizure medication levels, menopausal symptom relief, and seizure frequency and safety in menopausal women with epilepsy.
- Trial name
- NCT00027209
- Testing
- prempro
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Epilepsy
Study of Intranasal Clonazepam in Adult Subjects With Epileptic Seizures
Evaluate the safety and efficacy of intranasal Clonazepam in subjects with epilepsy.
- Trial name
- NCT00594945
- Testing
- Clonazepam
- Where
- 6 sites in United States, Finland
- Volunteers
- 45 people
- Sponsor
- Jazz Pharmaceuticals
Epilepsy
An Open-Label Interaction Study to Look at the Effects of Brivaracetam on Phenytoin When Taken Together in 15 Adult Patients With Epilepsy.
The primary objective of this Phase I study in 15 adult subjects suffering from epilepsy and chronically treated with phenytoin monotherapy is to evaluate the effect of steady-state ucb 34714 administration on the steady-state…
- Trial name
- NCT00426673
- Testing
- Brivaracetam (ucb34714)
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- UCB Pharma
Epilepsy
Women With Epilepsy: Pregnancy Outcomes and Deliveries
This is a three-center prospective case-control study to examine the patterns of fertility among women with epilepsy (WWE) compared to an age-matched group of women without epilepsy (WWoE).
- Trial name
- WEPOD (NCT01259310)
- Where
- 3 sites in United States
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Epileptic Seizures Related to Drugs, SARS-CoV-2 Acute Respiratory Disease
Epileptic Seizure in Epilepsy Patients After SARS-CoV-2 Vaccination
Background and Objectives: Seizure attack is one of adverse effects of vaccination in epileptic patients, the risk of which after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inoculation was elucidated in the…
- Conditions
- Epileptic Seizures Related to Drugs, SARS-CoV-2 Acute Respiratory Disease, Vaccine Adverse Reaction
- Trial name
- NCT05341713
- Testing
- inactive SARS-Cov-2 vaccine
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Xijing Hospital
Epilepsy, Epilepsy, Focal
A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.
The purpose of this study is to demonstrate that RWJ-333369 is safe and effective as add-on treatment of partial onset seizures.
- Conditions
- Epilepsy, Epilepsy, Focal, Seizure Disorder, Complex Partial Seizures
- Trial name
- NCT00425282
- Testing
- RWJ-333369
- Volunteers
- 566 people
- Sponsor
- SK Life Science, Inc.
Epilepsy
Exploring the Safety And Tolerability of Doses of E2007 up to a Maximum of 12 mg In Patients With Refractory Partial Seizures
This is a randomized, double-blind, placebo-controlled, parallel group study to determine the maximum tolerated dose of E2007. Epilepsy patients with refractory partial seizures will be divided into two groups of 24 patients…
- Trial name
- NCT00416195
- Testing
- E2007
- Where
- 2 sites in Latvia
- Volunteers
- 48 people
- Sponsor
- Eisai Co., Ltd.
Seizure Disorder, Partial
To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.
To evaluate long-term safety and efficacy of pregabalin in patients with partial seizures.
- Trial name
- NCT00141245
- Testing
- Pregabalin
- Where
- 46 sites in Australia, Austria and 11 more
- Volunteers
- 325 people
- Sponsor
- Pfizer
Mitochondrial Diseases, Drug Resistant Epilepsy
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy
This is a parallel-arm, double-blind, placebo-controlled study with a screening phase that includes a 28-day run-in phase to establish baseline seizure frequency, followed by a 24-week, randomized, placebo-controlled phase.
- Conditions
- Mitochondrial Diseases, Drug Resistant Epilepsy, Leigh Disease, Leigh Syndrome
- Trial name
- MIT-E (NCT04378075)
- Testing
- Vatiquinone
- Where
- 27 sites in United States, Canada and 7 more
- Volunteers
- 68 people
- Sponsor
- PTC Therapeutics
Dravet Syndrome, Lennox Gastaut Syndrome
A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome
This is an international, multicenter, open-label, long-term safety study of ZX008 in subjects with Dravet syndrome, Lennox-Gastaut syndrome or epileptic encephalopathy
- Conditions
- Dravet Syndrome, Lennox Gastaut Syndrome, Epileptic Encephalopathy
- Trial name
- NCT03936777
- Testing
- ZX008 (Fenfluramine Hydrochloride)
- Where
- 71 sites in United States, Australia and 12 more
- Volunteers
- 412 people
- Sponsor
- Zogenix, Inc.
Partial Epilepsy
Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
This is a multicenter, open label study to assess the safety and pharmacokinetics of YKP3089 as adjunctive therapy in subjects with partial onset seizures.
- Trial name
- NCT02535091
- Testing
- YKP3089
- Where
- 121 sites in United States, Argentina and 15 more
- Volunteers
- 1,345 people
- Sponsor
- SK Life Science, Inc.
Epilepsy
Study to Investigate Safety and Tolerability of Intravenous Lacosamide in Children.
EP0060 is a multicenter, open-label study to evaluate the safety and tolerability of intravenous (iv) Lacosamide (LCM) in pediatric subjects >= 1 month to < 17 years of age with epilepsy.
- Trial name
- ASPIRE (NCT02710890)
- Testing
- Lacosamide
- Where
- 23 sites in United States, Hungary and 3 more
- Volunteers
- 103 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Neonatal Seizure, Hypoxic-Ischemic Encephalopathy
Neonatal Seizure Registry - Developmental Functional EValuation
The NSR-DEV study is a longitudinal cohort study of around 280 Neonatal Seizure Registry participants that aims to evaluate childhood outcomes after acute symptomatic neonatal seizures, as well as examine risk factors for…
- Conditions
- Neonatal Seizure, Hypoxic-Ischemic Encephalopathy, Stroke, Intracranial Hemorrhages
- Trial name
- NSR-DEV (NCT04337697)
- Where
- 9 sites in United States
- Volunteers
- 188 people
- Sponsor
- University of California, San Francisco
Epilepsies, Partial
Compassionate Use Program With Lacosamide in Patients With Partial-onset or Generalized Tonic-clonic Seizures
The objective of this Compassionate Use Program (CUP) is to provide continued access to Lacosamide (LCM) for monotherapy use for patients who were receiving LCM in SP0993 and SP0994 at the time of study unblinding and close of…
- Trial name
- NCT03559673
- Testing
- Lacosamide
- Sponsor
- UCB Biopharma S.P.R.L.
Epilepsy; Seizure
Pharmacokinetics Study of Oral 2-Deoxy-D-Glucose (2DG) in Subjects With a Confirmed Diagnosis of Epilepsy
This project studies how 2-deoxy-glucose (2DG) pills are absorbed and distributed in people with epilepsy. 2DG is similar to glucose, the main energy source for the brain, but it cannot be used as energy.
- Trial name
- NCT05605301
- Testing
- Oral 2-Deoxy-D-Glucose (2DG)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Virginia
Partial Onset Seizures
An Extended Access Program for Perampanel
The Extended Access Program (EAP) is a managed access programme for Perampanel. The main objective of this EAP is to ensure that patients participating in studies E2007-A001-207, E2007-G000-307, or E2007-G000-235 continue to have…
- Trial name
- NCT01871233
- Testing
- Perampanel
- Where
- 78 sites in Argentina, Australia and 19 more
- Sponsor
- Eisai Inc.
Seizures Associated With EMAS
Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures
The primary aim of Part A of the study to assess the efficacy and tolerability of GWP42003-P compared to placebo as an adjunctive treatment for children with Epilepsy with myoclonic-atonic seizures (EMAS) -associated seizures.
- Trial name
- NCT05288283
- Testing
- GWP42003-P
- Where
- 14 sites in United States, Italy
- Volunteers
- 3 people
- Sponsor
- Jazz Pharmaceuticals
Seizure
The Clinical Application and Mechanism of Music Therapy (Mozart's Effect) on Epilepsy
Music has a long history in healing physical and mental illness. The Mozart effect was initially reported by Rauscher, Shaw, and Ky in the journal of "Nature" in the year of 1993.
- Trial name
- NCT01892605
- Testing
- music listening
- Where
- Taiwan
- Volunteers
- 46 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital